Pfizer, in partnership with Bristol Myers Squibb, has launched a direct-to-patient sales strategy for Eliquis®, aiming to ...

Analysts expect strong Netflix quarterly earnings, even as growth from its password-sharing clampdown slows. Here's what Wall ...

Netflix had success with "Squid Game" in the second quarter, but investors and analysts want to know what's next outside the ...

In the first quarter, the Frito-Lay maker posted its first quarterly profit miss in at least five years. PepsiCo's revenue ...

Analysts expect Johnson & Johnson to report an earnings per share (EPS) of $2.67. Johnson & Johnson bulls will hope to hear ...

Pfizer (PFE) ended the recent trading session at $25.35, demonstrating a -1.17% change from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily gain of 0.14%.

Pfizer is expected to announce its second-quarter results next month, and analysts predict a single-digit drop in the company ...

With a market cap of $21.8 billion, T. Rowe Price Group, Inc. (TROW) is a global investment management firm serving ...

The investment community will be closely monitoring the performance of Pfizer in its forthcoming earnings report. The company is scheduled to release its earnings on August 5, 2025.

Pfizer: Competitive Advantages Still Exist, but Signs of Erosion Lead Us to Lower Our Valuation We’ve also reduced the firm’s moat rating from wide to narrow.

Pfizer (PFE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.